BibTex RIS Kaynak Göster

Bisphosphonates And New Treatment Approachs of Bisphosphonate Related Osteonecrosis of the Jaws İn Oral And Maxillofacial Surgery

Yıl 2012, Cilt: 5 Sayı: 4, 1052 - 1062, 01.01.2012

Ezgi Karaçelebi Mustafa Öztürk

Öz

The use of biphosphonates for the treatment of osteoporosis and malignant tumors has caused an increase in the incident of osteonecrosis of the jaw recently. Therefore, oral maxillofacial surgeons have begun to investigate the relationship of between bisphosphonates and jaw osteonecrosis, treatment of jaw osteonecrosis. The purpose of this review is giving information about the mechanism of action of bisphosphonates, their use and the new treatment approachs of bisphosphonate-related osteonecrosis

Anahtar Kelimeler

Bifosfonat Çene osteonekrozu

Kaynakça

  • Soydan S., Veziroglu F., Araz K. Bifosfonata Bağlı Olarak Çene Kemiklerinde Gelişen Osteo- nekrozun Patogenezi ve Tedavisi. Hacettepe Diş Hekimliği Fakültesi Dergisi. 33:61-68, 2009.
  • Fleisch H. Development of bisphosphonates. Bre- ast Cancer Res. 4:30-34, 2002
  • Yıldız N., Alpay H. Use of Biphosphonates in Pe- diatric Nephrology Biphosphonates in Pediatric. Turkish Nephrology, Dialysis and Transplantation Journal. 20:132-141, 2011
  • Ruggiero S., Dodson TB., Assael LA., Landesberg R., Marx RE., Mehrotra B. American Association of Oral and Maxillofacial Surgeons Position Pa- per on Bisphosphonate-Related Osteonecrosis of the Jaw. Aust. Endod. J. 35:119-130, 2009
  • Zafersoy Z., Kahraman S. Kemik Metastazı Yap- mış Prostat Kanseri Tedavisinde Kullanılan Bifos- fonata Bağlı Olarak Çene Kemiklerinde Gelişen Osteonekroz: Vaka Raporu Ve Literatür Derleme- si. Atatürk Üniv. Diş. Hek. Fak. Derg. 18:105- 110, 2008.
  • Fournier P., Boissier S., Filleur S., Guglielmi J., Cabon F., Colombel M., Clézardin P. Bisp- hosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 62:6538-6544, 2002.
  • Giuliani N., Pedrazzoni M., Passeri G., Giraso- le G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand. J. Rheumatol. 27:38-41,1998.
  • Watts N. Treatment of osteoporosis with bisp- hosphonates. Endocrinol. Metab. Clin. North Am. 27:419-439, 1998.
  • Tuncer B. Bifosfonatlar ve Diş Hekimliği. SÜ Diş- hek. Fak. Derg. 16:57-60, 2007.
  • Woo SB., et al. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann. Intern. Med. 144:753–761, 2006.
  • Scoletta M.,Arduino PG., Dalmasso P., Broccolet- ti R., Mozzati M. Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study. Oral Surg. Oral Med. Oral Radiol. Endod. 110:46-53, 2010.
  • Ruggiero SL.,Mehrotra B., Rosenberg TJ., Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 62:527-534, 2004.
  • Almăşan HA., Băciuţ M., Rotaru H., Bran S, Almăşan O.C., Băciuţ G. Osteonecrosis of the jaws asso- ciated with the use of bisphosphonates Discus- sion over 52 cases. Rom. J. Morphol. Embryol. 52:1233–1241, 2011.
  • Tanvetyanon T., Stiff PJ. Management of the ad- verse effects associated with intravenous bisp- hosphonate. Annals of Oncology. 17: 897–907, 2006.
  • Rizzoli R., Burlet N., Cahall D, Delmas PD., Erik- sen EF., Felsenberg D., Grbic J., Jontell M., Lan- desberg R., Laslop A., Wollenhaupt M., Papa- poulos S., Sezer O., Sprafka M., Reginster JY. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 42:841-847, 2008.
  • Marx RE. Oral and intravenous bisphosphonate- induced osteonecrosis of the jaws: history, eti- logy, prevention, and treatment. Ouintessence Publishing Co, 2012, 45-86.
  • Cetiner S., Sucak G., Kahraman S., Akı SZ., Ko- cakahyaoglu B., Gultekin SB., Cetiner M., Haz- nedar R. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. J. Bone Miner. Metab. 27:435-443, 2009.
  • O’Ryan FS., Khoury S., Liao W., Han MM., Hui RL., Baer D., Martin D., Liberty D., Lo JC. Intra- venous bisph osphonate related osteonecrosis of the jaws; bone scintigraphy as an early indicator. J. Oral Maxillofac. Surg. 67:1363-1372, 2009.
  • Lazarovici TS., Mesilaty-Gross S., Vered I., Pari- ente C., Kanety H., Givol N., Yahalom R., Taic- her S., Yarom N. Serologic bone markers for pre- dicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J. Oral Maxillofac. Surg. 68:2241-2247, 2010.
  • Michael A., James R. The treatment of bisphosp- honateassociated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. JADA. 138:971-977, 2007.
  • Cicciù M., Herford A.S., Juodžbalys G., Stoffella E. Recombinant human bone morphogenetic pro- tein type 2 application for a possible treatment of bisphosphonates-related osteonecrosis of the jaw. J. Craniofac. Surg. 23:784-788, 2012.
  • Curi M., Cossolin G.S., Koga D.H., Zardetto C., Christianini S., Feher O., Cardoso C.L., dos San- tos M.O. Bisphosphonate-related osteonecrosis of the jaws-an initial case series report of treatment combining partial bone resection and autologo- us platelet-rich plasma. J. Oral Maxillofac. Surg. 69:2465-2472, 2011.
  • Atalay B., Yalcin S., Emes Y., Aktas I., Aybar B., Issever H., Mandel N.M., Cetin O., Oncu B. Bisphosphonate-related osteonecrosis: laser- assisted surgical treatment or conventional sur- gery. Lasers Med. Sci. 26:815-823, 2011.
  • Epstein M., Wicknick F.W., Epstein J.B., Berenson J.R., Gorsky M. Management of bisphosphonate- associated osteonecrosis: pentoxifylline and to- copherol in addition to antimicrobial therapy. An initial case series. Oral Surg. Oral Med. Oral Pat- hol. Oral Radiol. Endod. 110:593-596, 2010.
  • Erkan M., Bilgi O., Mutluoglu M., Uzun G. Bisphosphonate-Related Osteonecrosis of the Jaw in Cancer Patients and Hyperbaric Oxygen The- rapy. J. Pancreas. 10:579-580, 2009.
  • Narai S., Nagahata S. Effects of alendronate on the removal torque of implants in rats with in- duced osteoporosis. Int. J. Oral Maxillofac. Imp- lants. 18:218-223, 2003.
  • Astrand J., Aspenberg P. Reduction of instability- induced bone resorption using bisphosphonates: high doses are needed in rats. Acta Orthop. Scand. 73:24-30, 2002.
  • Eberhardt C., Schwarz M., Kurth A.H. High do- sage treatment of nitrogen-containing bisphosp- honate ibandronate is required for osseointegra- tion of cementless metal implants. J. Orthop. Sci. 10:622-626, 2005.
  • Flichy-Fernández A., Balaguer-Martínez J., Peñarrocha-Diago M., Bagán J.V. Bisphospho- nates and dental implants: current problems. Med. Oral Patol. Oral Cir. Bucal. 14:E355-E60, 2009.
  • American Association of Oral and Maxillofaci- al Surgeons Position Paper on Bisphosphonate- Related Osteonecrosis of the Jaws. J. Oral Maxil- lofac. Surg. 65:359-376, 2007.

Oral Ve Maksillofasial Cerrahide Bifosfonatlar Ve Bifosfonatla İlişkili Çene Osteonekrozu Tedavisinde Yeni Yaklaşımlar

Yıl 2012, Cilt: 5 Sayı: 4, 1052 - 1062, 01.01.2012

Ezgi Karaçelebi Mustafa Öztürk

Öz

Bifosfonatların; osteoporoz ve malign tümör tedavisinde kullanılmasıyla, günümüzde çene osteonekrozunun görülme sıklığını artmıştır. Bu nedenle, oral maksillofasial cerrahlar bifosfonatlar ile çene osteonekrozunun ilişkisini ve çene osteonekrozunun tedavisini araştırmaya başlamışlardır. Bu derlemede bifosfonatların etki mekanizması, kullanım alanları ve bifosfonata bağlı oluşan osteonekrozların tedavisinde uygulanan yeni tedavi protokolleri hakkında bilgi verilmesi amaçlanmıştır

Anahtar Kelimeler

Bisphosphonate Jaw osteonecrosis

Kaynakça

  • Soydan S., Veziroglu F., Araz K. Bifosfonata Bağlı Olarak Çene Kemiklerinde Gelişen Osteo- nekrozun Patogenezi ve Tedavisi. Hacettepe Diş Hekimliği Fakültesi Dergisi. 33:61-68, 2009.
  • Fleisch H. Development of bisphosphonates. Bre- ast Cancer Res. 4:30-34, 2002
  • Yıldız N., Alpay H. Use of Biphosphonates in Pe- diatric Nephrology Biphosphonates in Pediatric. Turkish Nephrology, Dialysis and Transplantation Journal. 20:132-141, 2011
  • Ruggiero S., Dodson TB., Assael LA., Landesberg R., Marx RE., Mehrotra B. American Association of Oral and Maxillofacial Surgeons Position Pa- per on Bisphosphonate-Related Osteonecrosis of the Jaw. Aust. Endod. J. 35:119-130, 2009
  • Zafersoy Z., Kahraman S. Kemik Metastazı Yap- mış Prostat Kanseri Tedavisinde Kullanılan Bifos- fonata Bağlı Olarak Çene Kemiklerinde Gelişen Osteonekroz: Vaka Raporu Ve Literatür Derleme- si. Atatürk Üniv. Diş. Hek. Fak. Derg. 18:105- 110, 2008.
  • Fournier P., Boissier S., Filleur S., Guglielmi J., Cabon F., Colombel M., Clézardin P. Bisp- hosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 62:6538-6544, 2002.
  • Giuliani N., Pedrazzoni M., Passeri G., Giraso- le G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand. J. Rheumatol. 27:38-41,1998.
  • Watts N. Treatment of osteoporosis with bisp- hosphonates. Endocrinol. Metab. Clin. North Am. 27:419-439, 1998.
  • Tuncer B. Bifosfonatlar ve Diş Hekimliği. SÜ Diş- hek. Fak. Derg. 16:57-60, 2007.
  • Woo SB., et al. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann. Intern. Med. 144:753–761, 2006.
  • Scoletta M.,Arduino PG., Dalmasso P., Broccolet- ti R., Mozzati M. Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study. Oral Surg. Oral Med. Oral Radiol. Endod. 110:46-53, 2010.
  • Ruggiero SL.,Mehrotra B., Rosenberg TJ., Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 62:527-534, 2004.
  • Almăşan HA., Băciuţ M., Rotaru H., Bran S, Almăşan O.C., Băciuţ G. Osteonecrosis of the jaws asso- ciated with the use of bisphosphonates Discus- sion over 52 cases. Rom. J. Morphol. Embryol. 52:1233–1241, 2011.
  • Tanvetyanon T., Stiff PJ. Management of the ad- verse effects associated with intravenous bisp- hosphonate. Annals of Oncology. 17: 897–907, 2006.
  • Rizzoli R., Burlet N., Cahall D, Delmas PD., Erik- sen EF., Felsenberg D., Grbic J., Jontell M., Lan- desberg R., Laslop A., Wollenhaupt M., Papa- poulos S., Sezer O., Sprafka M., Reginster JY. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 42:841-847, 2008.
  • Marx RE. Oral and intravenous bisphosphonate- induced osteonecrosis of the jaws: history, eti- logy, prevention, and treatment. Ouintessence Publishing Co, 2012, 45-86.
  • Cetiner S., Sucak G., Kahraman S., Akı SZ., Ko- cakahyaoglu B., Gultekin SB., Cetiner M., Haz- nedar R. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. J. Bone Miner. Metab. 27:435-443, 2009.
  • O’Ryan FS., Khoury S., Liao W., Han MM., Hui RL., Baer D., Martin D., Liberty D., Lo JC. Intra- venous bisph osphonate related osteonecrosis of the jaws; bone scintigraphy as an early indicator. J. Oral Maxillofac. Surg. 67:1363-1372, 2009.
  • Lazarovici TS., Mesilaty-Gross S., Vered I., Pari- ente C., Kanety H., Givol N., Yahalom R., Taic- her S., Yarom N. Serologic bone markers for pre- dicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J. Oral Maxillofac. Surg. 68:2241-2247, 2010.
  • Michael A., James R. The treatment of bisphosp- honateassociated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. JADA. 138:971-977, 2007.
  • Cicciù M., Herford A.S., Juodžbalys G., Stoffella E. Recombinant human bone morphogenetic pro- tein type 2 application for a possible treatment of bisphosphonates-related osteonecrosis of the jaw. J. Craniofac. Surg. 23:784-788, 2012.
  • Curi M., Cossolin G.S., Koga D.H., Zardetto C., Christianini S., Feher O., Cardoso C.L., dos San- tos M.O. Bisphosphonate-related osteonecrosis of the jaws-an initial case series report of treatment combining partial bone resection and autologo- us platelet-rich plasma. J. Oral Maxillofac. Surg. 69:2465-2472, 2011.
  • Atalay B., Yalcin S., Emes Y., Aktas I., Aybar B., Issever H., Mandel N.M., Cetin O., Oncu B. Bisphosphonate-related osteonecrosis: laser- assisted surgical treatment or conventional sur- gery. Lasers Med. Sci. 26:815-823, 2011.
  • Epstein M., Wicknick F.W., Epstein J.B., Berenson J.R., Gorsky M. Management of bisphosphonate- associated osteonecrosis: pentoxifylline and to- copherol in addition to antimicrobial therapy. An initial case series. Oral Surg. Oral Med. Oral Pat- hol. Oral Radiol. Endod. 110:593-596, 2010.
  • Erkan M., Bilgi O., Mutluoglu M., Uzun G. Bisphosphonate-Related Osteonecrosis of the Jaw in Cancer Patients and Hyperbaric Oxygen The- rapy. J. Pancreas. 10:579-580, 2009.
  • Narai S., Nagahata S. Effects of alendronate on the removal torque of implants in rats with in- duced osteoporosis. Int. J. Oral Maxillofac. Imp- lants. 18:218-223, 2003.
  • Astrand J., Aspenberg P. Reduction of instability- induced bone resorption using bisphosphonates: high doses are needed in rats. Acta Orthop. Scand. 73:24-30, 2002.
  • Eberhardt C., Schwarz M., Kurth A.H. High do- sage treatment of nitrogen-containing bisphosp- honate ibandronate is required for osseointegra- tion of cementless metal implants. J. Orthop. Sci. 10:622-626, 2005.
  • Flichy-Fernández A., Balaguer-Martínez J., Peñarrocha-Diago M., Bagán J.V. Bisphospho- nates and dental implants: current problems. Med. Oral Patol. Oral Cir. Bucal. 14:E355-E60, 2009.
  • American Association of Oral and Maxillofaci- al Surgeons Position Paper on Bisphosphonate- Related Osteonecrosis of the Jaws. J. Oral Maxil- lofac. Surg. 65:359-376, 2007.
Toplam 30 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Research Article
Yazarlar

Ezgi Karaçelebi Bu kişi benim

Mustafa Öztürk Bu kişi benim

Yayımlanma Tarihi 1 Ocak 2012
Yayımlandığı Sayı Yıl 2012 Cilt: 5 Sayı: 4

Kaynak Göster

Vancouver Karaçelebi E, Öztürk M. Oral Ve Maksillofasial Cerrahide Bifosfonatlar Ve Bifosfonatla İlişkili Çene Osteonekrozu Tedavisinde Yeni Yaklaşımlar. ADO Klinik Bilimler Dergisi. 2012;5(4):1052-6.